PreprintAll rights reservedbioRxiv
The Smac mimetic drug Xevinapant sensitizes triple negative breast cancer to radiotherapy-induced cell death in a TNFα dependent manner
- 1Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM)
Related
- CCNE1 overexpression drives a cGAS-STING-dependent interferon response and sensitizes HRD-positive ovarian cancer to immune checkpoint blockade.
- TRPML1 loss disrupts lysosome–mitochondria homeostasis and sensitizes MDA-MB-231 triple-negative breast cancer cells to chemotherapy
- PGG Enhances Olaparib Efficacy via cGAS-STING Signaling and Sensitizes Triple-Negative Breast Cancer to PD- L1 Blockade
- Targeting ribosome biogenesis sensitizes PARPi-resistant triple-negative breast cancer
- Fibrillarin Resists Cellular Senescence Via SIRT1‐Dependent Nicotinamide Metabolism and Its Inhibition Sensitizes Senolytic Therapy in Esophageal Squamous Cell Carcinoma
BibTeX
@misc{faye2026smac,
title = {{The Smac mimetic drug Xevinapant sensitizes triple negative breast cancer to radiotherapy-induced cell death in a TNFα dependent manner}},
author = {M. D. Faye and J. Lafontaine and P. Wong and C. Menard},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.29.755558},
url = {https://www.biorxiv.org/content/10.64898/2026.09.29.755558v1},
}
RIS
TY - UNPB
TI - The Smac mimetic drug Xevinapant sensitizes triple negative breast cancer to radiotherapy-induced cell death in a TNFα dependent manner
AU - M. D. Faye
AU - J. Lafontaine
AU - P. Wong
AU - C. Menard
PY - 2026
DA - 2026/09/29
PB - bioRxiv
DO - 10.64898/2026.09.29.755558
UR - https://www.biorxiv.org/content/10.64898/2026.09.29.755558v1
ER -